Reuters

U.S. resumes supply of Lilly’s COVID-19 antibody combo to some states

The Department of Health and Human Services narrowed the scope of authorization for the dual-antibody therapy, bamlanivimab and etesevimab, to states including Colorado, Connecticut and Illinois, Indiana. With the Delta variant becoming the dominant strain, the prevalence of variants resistant to the therapy is steadily decreasing, the agency said https://www.phe.gov/emergency/events/COVID19/investigation-MCM/Bamlanivimab-etesevimab/Pages/resumption-in-distribution-bamlanivimabetesevimab.aspx. Based on lab tests, the drugs administered together are expected to retain activity against the Delta variant, but not against Delta plus and variants first identified in Brazil, South Africa and Colombia, it said.

LEAVE A REPLY

Please enter your comment!
Please enter your name here